ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Dainippon Sumitomo Pharma has agreed to acquire Boston Biomedical Inc. for $200 million. Based in Norwood, Mass., BBI is developing two small-molecule drugs that work by targeting cancer stem cells. One, BBI608, is being prepared for a Phase III clinical trial as a colorectal cancer treatment and is in Phase Ib and II trials for various solid tumors. The other, BBI503, is in Phase I trials for solid tumors. Under the deal, BBI’s six shareholders also can get up to $540 million in developmental milestone payments. Dainippon Sumitomo licensed Japanese rights to BBI608 in March 2011.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X